Maternal and fetal outcomes in pregnancies with obstructive sleep apnea

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Eloise Passarella ◽  
Nicholas Czuzoj-Shulman ◽  
Haim A. Abenhaim

Abstract Objectives Obstructive sleep apnea (OSA) is linked to many health comorbidities. We aimed to ascertain if OSA correlates with a rise in poor obstetrical outcomes. Methods Employing the United States’ Healthcare Cost and Utilization Project – National Inpatient Sample, we performed our retrospective cohort study including all women who delivered between 2006 and 2015. ICD-9 codes were used to characterize women as having a diagnosis of OSA. Temporal trends in pregnancies with OSA were studied, baseline features were evaluated among gravidities in the presence and absence of OSA, and multivariate logistic regression analysis was utilized in assessing consequences of OSA on patient and newborn outcomes. Results Of a total 7,907,139 deliveries, 3,115 belonged to patients suffering from OSA, resulting in a prevalence of 39 per 100,000 deliveries. Rates rose from 10.14 to 78.12 per 100,000 deliveries during the study interval (p<0.0001). Patients diagnosed with OSA were at higher risk of having pregnancies with preeclampsia, OR 2.2 (95% CI 2.0–2.4), eclampsia, 4.1 (2.4–7.0), chorioamnionitis, 1.4 (1.2–1.8), postpartum hemorrhage, 1.4 (1.2–1.7), venous thromboembolisms, 2.7 (2.1–3.4), and to deliver by caesarean section, 2.1 (1.9–2.3). Cardiovascular and respiratory complications were also more common among these women, as was maternal death, 4.2 (2.2–8.0). Newborns of OSA patients were at elevated risk of being premature, 1.3 (1.2–1.5) and having congenital abnormalities, 2.3 (1.7–3.0). Conclusions Pregnancies with OSA were linked to an elevated risk of poor maternal and neonatal outcomes. During pregnancy, OSA patients should receive attentive follow-up care in a tertiary hospital.

SLEEP ◽  
2014 ◽  
Vol 37 (5) ◽  
pp. 843-849 ◽  
Author(s):  
Judette M. Louis ◽  
Mulubrhan F. Mogos ◽  
Jason L. Salemi ◽  
Susan Redline ◽  
Hamisu M. Salihu

SLEEP ◽  
2020 ◽  
Vol 43 (Supplement_1) ◽  
pp. A280-A281
Author(s):  
S E Neill ◽  
R Majid

Abstract Introduction The annual cost of diagnosis and treatment of obstructive sleep apnea (OSA) exceeds 12.4 billion dollars in the United States. The Centers for Medicare and Medicaid Services (CMS) require that after initiation of positive airway pressure (PAP) therapy patients have physician follow up and comply with specific requirements. Otherwise, continued PAP benefits are terminated and patients must undergo repeat sleep testing to reinstate therapy. Repeat testing can become an economic burden. We hypothesize that restudying patients prior to reinstating PAP therapy does not change the diagnosis and may only result in increased health care costs. Methods A chart review of polysomnographic studies (PSG) was performed on Medicare referrals made for the purposes of recertification to the Memorial Hermann Sleep center between October 2018 and 2019. Demographic and diagnostic data (including AHI) were collected. The percentage of patients with a change of diagnosis between the initial study and the recertification study was documented. Results 429 Medicare patients were referred for polysomnography. 34 patients were referred for PAP recertification. The average age in the recertification group was 65 years, 47% were male with an average BMI of 33.4 kg/m2. The average AHI on the recertification study was 33.5 events/hour (range 7-114). None of the patients sent for PAP recertification by polysomnography had a negative study for OSA. Conclusion Repeat PSG did not change the need for PAP therapy in patients originally diagnosed with OSA (all the patients continued to qualify). The mandatory referral of all patients who do not meet the CMS requirements for continued benefits for PAP, represents an extra cost to the health care system without a change in the clinical therapy. This money may better be utilized in providing patient education known to improve adherence to PAP. Support N/A


Author(s):  
Maria Paula Henao ◽  
Jennifer L. Kraschnewski ◽  
Matthew D. Bolton ◽  
Faoud Ishmael ◽  
Timothy Craig

Background: Inhaled corticosteroids (ICS) produce local effects on upper airway dilators that could increase the risk of developing obstructive sleep apnea (OSA). Given that the particle size of ICS changes their distribution, the particle size of ICS may impact the risk of developing OSA. Objectives: In this large retrospective study, we explore the relationship of ICS use and OSA in patients with asthma. In addition, we seek to determine if this relationship is affected by the particle size of ICS. Methods: Using electronic health records, we established a cohort of 29,816 asthmatics aged 12 and older with a diagnosis of asthma documented by ICD-9 or ICD-10 codes between January 2011 and August 2016. We performed analyses of variance and multivariate logistic regression analysis to determine the effects ICS on the diagnosis of OSA with sub-analysis by particle size of ICS. Results: Uncontrolled asthmatics showed increased odds of receiving a diagnosis of OSA whether when looking at ACT scores (adjusted odds ratio (aOR) 1.60, 95% CI 1.32–1.94) or PFT results (aOR 1.45, 95% CI 1.19–1.77). Users of ICS also had increased odds of OSA independent of asthma control (aOR 1.58, 95% CI 1.47–1.70). Notably, users of extra-fine particle ICS did not have significantly increased odds of having OSA compared to non-users of ICS (aOR 1.11, 95% CI 0.78–1.58). Conclusions: Use of ICS appears to be an independent risk factor for OSA. Notably, extra-fine particle size ICS do not appear to be associated with an increased risk of OSA.


2020 ◽  
Vol 3 (06) ◽  
pp. 478-486
Author(s):  
Joanna Suomi ◽  
Gregory Hess ◽  
Christine Won ◽  
Morgan Bron ◽  
John Acquavella

Background: The prevalence of obstructive sleep apnea (OSA) has not been assessed within the United States (US) in over adecade. Objectives:From 2013 to 2016, we calculated annual 2-year limited duration prevalence of diagnosed OSA in a large (~66million), geographically diverse insured population. We evaluated trends by age and sex; and assessed positive airway pressure (PAP) use and excessive sleepiness (hypersomnia diagnosis, or prescriptions for stimulant or wake-promoting agent [WPA]). Methods:Overall and age/sex specific prevalence per 100 insured persons was calculated on an annual basis. The cohort was defined to include those with medical and pharmacy claims activity. To mitigate rule-out diagnoses,cases had to have ≥2 medical claims for OSA within a 6-month period. Overall annual prevalences were directly standardized to the US population using 2016 US age and sex Census weights. Results: Annualage/sex adjusted prevalence of OSA increased from 2.4% in 2013 to 3.4% in 2016. OSA patients had a mean age of 58 years and there was a ≈2:1 male:female prevalence ratio. OSA patients with PAP claims increased from 42.2% to 44.1% over the study period. Excessive sleepiness (hypersomnia or stimulant/WPA prescriptions) for patients with or without PAP use both declined by ≈ 4% -5%. Conclusions:Diagnosed OSA prevalence and PAP use among insured members with claims activity increased during 2013-2016 while clinical markers of excessive sleepiness declined.   Males had a much higher prevalence of OSA than females.


2021 ◽  
Author(s):  
Shefali Kumar ◽  
Emma Rudie ◽  
Cynthia Dorsey ◽  
Amy Blase ◽  
Adam V Benjafield ◽  
...  

BACKGROUND Despite the importance of diagnosis and treatment, obstructive sleep apnea (OSA) remains a vastly underdiagnosed condition; this is partially due to current OSA identification methods and a complex and fragmented diagnostic pathway. OBJECTIVE This prospective, single-arm, multistate feasibility pilot study aimed to understand the journey in a nonreferred sample of participants through the fully remote OSA screening and diagnostic and treatment pathway, using the Primasun Sleep Apnea Program (formally, Verily Sleep Apnea Program). METHODS Participants were recruited online from North Carolina and Texas to participate in the study entirely virtually. Eligible participants were invited to schedule a video telemedicine appointment with a board-certified sleep physician who could order a home sleep apnea test (HSAT) to be delivered to the participant's home. The results were interpreted by the sleep physician and communicated to the participant during a second video telemedicine appointment. The participants who were diagnosed with OSA during the study and prescribed a positive airway pressure (PAP) device were instructed to download an app that provides educational and support-related content and access to personalized coaching support during the study’s 90-day PAP usage period. Surveys were deployed throughout the study to assess baseline characteristics, prior knowledge of sleep apnea, and satisfaction with the program. RESULTS For the 157 individuals who were ordered an HSAT, it took a mean of 7.4 (SD 2.6) days and median 7.1 days (IQR 2.0) to receive their HSAT after they completed their first televisit appointment. For the 114 individuals who were diagnosed with OSA, it took a mean of 13.9 (SD 9.6) days and median 11.7 days (IQR 10.1) from receiving their HSAT to being diagnosed with OSA during their follow-up televisit appointment. Overall, the mean and median time from the first televisit appointment to receiving an OSA diagnosis was 21.4 (SD 9.6) days and 18.9 days (IQR 9.2), respectively. For those who were prescribed PAP therapy, it took a mean of 8.1 (SD 9.3) days and median 6.0 days (IQR 4.0) from OSA diagnosis to PAP therapy initiation. CONCLUSIONS These results demonstrate the possibility of a highly efficient, patient-centered pathway for OSA workup and treatment. Such findings support pathways that could increase access to care, reduce loss to follow-up, and reduce health burden and overall cost. The program’s ability to efficiently diagnose patients who otherwise may have not been diagnosed with OSA is important, especially during a pandemic, as the United States shifted to remote care models and may sustain this direction. The potential economic and clinical impact of the program’s short and efficient journey time and low attrition rate should be further examined in future analyses. Future research also should examine how a fast and positive diagnosis experience impacts success rates for PAP therapy initiation and adherence. CLINICALTRIAL ClinicalTrials.gov NCT04599803; https://clinicaltrials.gov/ct2/show/NCT04599803


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 2444-2444 ◽  
Author(s):  
Radhika Gangaraju ◽  
Krishna M Sundar ◽  
Jihyun Song ◽  
Josef T. Prchal

Abstract There is a high prevalence of obstructive sleep apnea (OSA) in the United States, with one-quarter of adults aged 30 to 70 years having OSA. Most clinicians consider OSA as one of the causes of elevated hemoglobin (Hb) - polycythemia, but this is based on anecdotal evidence and further work up is often not pursued. Chronic intermittent hypoxia associated with OSA can augment hypoxia-inducible factor-2, the principal regulator of erythropoietin, and may increase red cell mass. But there is a paucity of published data evaluating the effects of OSA and treatment with continuous positive airway pressure (CPAP) on hematologic parameters. We conducted a retrospective analysis of 5152 patients evaluated for OSA with polysomnography at the University of Utah Sleep-Wake Center from January 2013 to October 2015. Hematologic, other laboratory and clinical parameters were available for 527 patients prior to and after therapy of OSA with CPAP. OSA severity was defined as mild (apnea hypopnea index (AHI) 5-15 events/hr), moderate (AHI 15-30/hr) or severe (AHI >30/hr). Data on AHI, lowest oxygen saturation (SpO2) and time spent at SpO2 < 89% were obtained from polysomnography. Other evaluated parameters were age, gender, body mass index, CBC prior to starting CPAP; and Hb and hematocrit (Hct) at 3, 6, 12 and 18 month time points during CPAP therapy. Information regarding comorbidities and medication use that could influence red cell mass was also collected. WHO criteria were used to define polycythemia as Hb >18.5 and 16.5 gm/dl in males and females, respectively. This study included 527 patients, 254 females (48.19%) and 273 males (51.8%), who had at least one Hb measurement prior to starting CPAP therapy. Twenty-one (4%) out of 527 patients had polycythemia, of which 12 were on testosterone supplementation or used home oxygen for chronic pulmonary disease. Excluding these 12 patients resulted in a lower prevalence of polycythemia in OSA of 1.7% (9 patients). JAK2 mutational status or erythropoietin levels, however, were not available for all patients. The polycythemic cohort included 6 females and 3 males with a mean age of 56.6 years. The mean AHI was 35.7; 3 patients had mild, 2 moderate, and 4 severe OSA. Common comorbidities included hypertension (n=5), stroke (n=2) and diabetes (n=2). The mean Hb before CPAP therapy was 17.4 gm/dl, which corrected to normal during CPAP usage in 7 but not in 2. In these 2 patients, Hb corrected to normal with CPAP usage, but increased again by 18 months despite continued CPAP use. The mean Hb was lowest after 3 months of CPAP use and gradually increased thereafter (Table 1). Analysis of mean Hb concentration between different OSA severities (mild, moderate and severe) did not show any significant difference (Table 2). However, when analysis was performed using the normal range for the laboratory used, an additional 16 (3%) patients had Hb above the upper limit of normal (15.9 gm/dl for females and 17.8 gm/dl for males). This resulted in a 7% prevalence of polycythemia in OSA. Excluding patients on testosterone or with chronic lung disease, the overall prevalence was 4.5% (24 patients). Seventeen (3.2%) patients had elevated Hct with normal Hb. Here we report the results from a large dataset of OSA patients measuring the prevalence of polycythemia. Our results show that polycythemia is rarely seen in OSA patients, and other potential causes of polycythemia should be evaluated before attributing it to OSA. The degree of OSA severity does not seem to correlate with Hb level. In those rare polycythemic OSA patients, polycythemia is corrected by CPAP therapy in the majority. However, with the revised WHO criteria for diagnosis of polycythemia vera (16 and 16.5 gm/dl for females and males, respectively), we anticipate that more patients with OSA will be considered to have polycythemia. The low prevalence of polycythemia may be attributed to neocytolysis, wherein transition from sustained hypoxia to normoxia leads to overcorrection of polycythemia due to transient expansion of mitochondria-generating reactive oxygen species, with preferential destruction of young red cells made in hypoxia (Song et al, Mol Med, 2015). We are currently investigating whether neocytolysis also occurs in OSA, which however is characterized by chronic, rapid, repetitious cycles of hypoxia and normoxia that may preclude development of polycythemia in a majority of patients. First and second authors listed contributed equally. Disclosures No relevant conflicts of interest to declare.


2021 ◽  
pp. 019459982110646
Author(s):  
Mehmet Ali Babademez ◽  
Fatih Gul ◽  
Kadir Sinasi Bulut ◽  
Mecit Sancak ◽  
Saliha Kusoglu Atalay

Objective With the widespread use of drug-induced sleep endoscopy, it has been suggested that epiglottis pathologies are present at high rates in patients with sleep apnea. The aim of our study was to evaluate the efficacy of trimming the curled-inward epiglottis as an updated surgical technique in patients with omega epiglottis. Study Design Retrospective study. Setting Tertiary hospital. Methods Among the 283 patients with epiglottis pathology, 21 with isolated omega-shaped epiglottis (age, 33-53 years) fulfilled the inclusion criteria between May 2016 and April 2019. Drug-induced sleep endoscopy was used to detect epiglottic collapse compressed by the lateral parts during inspiration. An epiglottoplasty technique was applied as single-level sleep surgery in patients with an isolated omega-shaped epiglottis. The medical data were also reviewed. Results The mean pre- and postoperative total apnea-hypopnea index (AHI) scores were 27.89 and 10.58, respectively, and this difference was statistically significant ( P < .001). There was a statistically significant difference between the pre- and postoperative supine AHI scores (27.02 vs 10.48, P < .001). Surgical success, defined as AHI <20 and a decrease in AHI by 50%, was documented in 85.71% of patients (18/21), and 12 patients found complete relief from obstructive sleep apnea symptoms (AHI <5); the cure rate was 38.09% (8/21). Conclusion Trimming the curled-inward epiglottis may represent an excellent option for epiglottis surgery in patients with obstructive sleep apnea by being less invasive than techniques currently in use.


SLEEP ◽  
2021 ◽  
Vol 44 (Supplement_2) ◽  
pp. A218-A218
Author(s):  
Palakkumar Patel ◽  
Tomas Munoz ◽  
Pranshu Adavadkar

Abstract Introduction This study aimed to quantify the impact of obstructive sleep apnea (OSA) on the mortality, morbidity, and resources utilization among children admitted with Sickle cell crisis (SCC) Methods This is a retrospective analysis using the 2016 and 2017 National Inpatient Sample Database. The Inclusion Criteria was a principal Diagnosis of SSC and age &lt;18 years. OSA, as a Secondary Diagnosis, was identified using the appropriate ICD-10 CM codes. The Primary Outcomes were Inpatient Mortality, and secondary outcomes were: In-Hospital Length of Stay(LOS), Total hospitalization Cost, Blood transfusion (BT) requirement, and a requirement for Invasive mechanical ventilation (IMV). We used Multivariate Linear/ logistic regression to adjust for confounders including age and sex. Results Out of 36,484 children with SSC included in the study, 1450 children had OSA (SCC+OSA). SSC-OSA and SSC+OSA groups did not differ in gender, household income, and hospital characteristics, but did so in age (11.3 vs 12.4; p &lt;0.001). OSA was most common in the age group of 13–18 (54%) and lowest in 0–4 (2.4%). Compared to SSC-OSA, the SCC+OSA cohort had significantly higher odds of mortality (adjusted OR= 11.9, [95% Confidence Interval: 1.02- 138.8],p=0.04). Additionally, SSC+OSA cohort was associated with increased odds of IMV (aOR=5.24 [CI: 1.84 – 14.8], p=0.002), longer LOS (adjusted mean difference (aMD)=0.67 [CI-0.32 – 1.02], p=&lt;0.001), and higher hospitalization Cost (aMD=2818.76 [CI-1680- 4157], p=&lt;0.001). No difference in BT (aOR=0.94 [CI: 0.68 – 1.29], p=0.71) was noted. Conclusion This study demonstrates that the presence of OSA is associated with detrimental outcomes in SSC with higher in-hospital mortality, higher morbidity (Invasive mechanical ventilation rate), and higher resource utilization (LOS, total hospitalization cost). More attention to the screening, early diagnosis, and appropriate treatment of OSA is imperative to improve health outcomes in children with sickle cell disease. Support (if any):


Sign in / Sign up

Export Citation Format

Share Document